science_technology_and_other_research_and_development · DOD-AMRAA

DoW Arthritis Translational Research Award

Defense Health Agency Contracting Activity - DHACA · HT942526ATRPTRA

57 days left

Total Program Funding

$1.6M

Expected Awards

Deadline

October 22, 2026

GRANTQUICK SUMMARYPlain-English Overview

DoW Arthritis Translational Research Award. Defense Health Agency Contracting Activity - DHACA. Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be... $1,600,000 total program funding; ~2 awards expected.

Who Should Apply

Unrestricted (any eligible entity)

Who Should NOT Apply

Few restrictions — most eligible entities can apply

Key Requirements (Plain English)

•Deadline: 2026-10-22

💡 GrantQuick Tip

High-value award — invest significantly in proposal quality. Consider hiring a grant writer.

Competitiveness: Very high — extremely limited awards available

What This Grant Funds

Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to Service Members, Veterans, their Families and the American public. Research addressing any and all types of arthritis is encouraged.

Distinctive Features: The FY26 ATRP TRA mechanism is intended to support preclinical or animal research and may not be used for clinical research or clinical trials. Basic research, as defined in Section 3.1.2, is not allowed. A key aspect of this award mechanism is impact. The application should explicitly state how outcomes of the proposed research will significantly advance arthritis research, particularly in accelerating critical findings into clinically relevant solutions.

Preliminary and/or published data, originating from research conducted by the applicant(s) or others, is required.